amgen

Insiders may sell shares for any number of reasons, but there is really only one reason insiders buy shares of a company -- they believe the stock price will move higher and they want to profit from it. Pullbacks and sell-offs provide a perfect opportunity for investors who have faith in a company...

The earnings crunch is in full swing this this week. Quarterly results are due from the likes of Caterpillar (NYSE: CAT), Exxon Mobil (NYSE: XOM), Procter & Gamble (NYSE: PG) and United Parcel Service (NYSE: UPS), from which analysts expect to see year-over-year earnings growth, as well as...

Piper Jaffray has published a report on Amgen (NASDAQ: AMGN) covering individual product lines. In the report, Piper Jaffray wrote, "Amgen reported 2Q earnings that were well above consensus expectations, with most major product lines coming in ahead and Epogen sales meeting Street forecasts. Both...

The earnings crunch continues this week even as the month of July winds to a close. Quarterly reports of note scheduled for the week include those from Netflix (NASDAQ: NFLX), United Parcel Service (NYSE: UPS), Exxon Mobil (NYSE: XOM), Starbucks (NASDAQ: SBUX), Merck (NYSE: MRK) and Dow Chemical (...

iShares Dow Jones US Healthcare Provider (NYSE: IHF) is up more than 19% year to date. The fund invests at least 90% of its assets in securities of the underlying index, which measures the performance of the health care providers sector of the U.S. equity market. Top holdings include UnitedHealth...

PowerShares S&P SmallCap Health Care (NYSE: PSCH) is up nearly 22% year to date. The investment seeks to replicate the S&P SmallCap 600 Capped Health Care index, which is comprised of common stocks of U.S. health care companies. Top holdings include Regeneron Pharmaceuticals (NASDAQ: REGN...

Goldman Sachs reiterated its Sell rating on Amgen (NASDAQ: AMGN). In today's trading, Amgen lost 0.31% of its value to trade around $58.47.

Oppenheimer is out with its report today on Amgen (NASDAQ: AMGN), maintaining Outperform. In a note to clients, Oppenheimer writes, "While the company is facing a number of regulatory and competitive headwinds, we believe revenues from Amgen's core franchises are nearing stabilization. We believe...

According to Jefferies, Amgen (NASDAQ: AMGN) estimates are maintained. Jefferies said that updated label removes a specific Hb target range (10-12 g/dL) and guides to individualize ESA therapy to reduce the need for red blood cell transfusions. Also, the label implies Hb target dose of 10-11 g/dL...

Piper Jaffray provided color on Amgen (NASDAQ: AMGN). In a research report published today, Piper Jaffray commented on possible FDA labeling changes to Epogen use in the dialysis setting. In the report, Piper Jaffray states, "Based on conversations with Amgen and several dialysis providers, we...

According to a recent report, J.P. Morgan has raised 2012-13 EPS estimates on Amgen (NASDAQ: AMGN) from $5.77/$5.77 to $5.82/$5.87 leading up to a 10 a.m. conference call today to discuss a recent survey J.P. Morgan conducted for the '147 trial. In the survey, J.P. Morgan talked to 25 urologist to...

Jefferies provided color on Amgen (NASDAQ: AMGN). In a research report report published today, Jefferies commented on the development of some of Amgen's new drugs. The report states, "Phase 2 data for ganitumab (AMG-479), the most advanced IGF-IR antagonist in development, shows a trend toward...

In a report released yesterday, Bank of America Merrill Lynch commented on Amgen (NASDAQ: AMGN). In the report, Bank of America Merrill Lynch was mixed in its outlook on the company. Bank of America Merrill Lynch writes, “Our price objective of $62 is supported by our sum-of-the-parts DCF: $15/sh...

Bank of America has raised the price target on Amgen (NASDAQ: AMGN) from $60 to $62 and maintains its Neutral rating.

According to J.P. Morgan, Amgen (NASDAQ: AMGN) target is raised to $70. J.P. Morgan said that Amgen's fundamentals are balanced by two primary issues: upside potential from Prolia/Xgeva (dmab) and downside risk from the anemia (ESA) franchise. “These two issues drive sentiment on AMGN shares and...